Most creative testing frameworks presume you can create a dozen variants overnight and leave the algorithm to separate winners from losers. Digital health does not work that way – each variant requires review, audiences are frequently narrow condition-specific cohorts, and a failed test may involve a claim that should never have gone live. We create a testing process designed around those real constraints.
The Challenge
Typical testing volume relies on review cycles that simply do not exist in your world
A typical performance marketing testing cadence runs ten or more creative variants a week to find statistical winners fast. If every variant needs legal or medical sign-off before it can run, that cadence collapses, and teams either slow testing to a crawl or start skipping review to keep pace, both of which create real problems. Nobody has rebuilt the testing framework around the actual throughput a compliance-gated pipeline can support.
Your most valuable audiences are too small to achieve statistical significance through the usual approach
A condition-specific cohort – a rare disease population, a narrow clinical indication, a specific benefits-eligible employer group – often does not have enough volume to run a standard multivariate test and reach confidence in a reasonable window. Teams either give up on testing these segments entirely, leaving real performance on the table, or they call underpowered results significant and make decisions on noise.
In this category, a losing creative test can cost more than wasted budget
In most industries a bad-performing ad just gets turned off. In digital health, a test variant that overstates a benefit or implies a clinical outcome you cannot substantiate can create real regulatory and reputational exposure even if it never gets flagged internally. Testing programs that treat every variant as low-risk because it is "just a test" are missing that the downside here is asymmetric.
No one is testing the variable that truly matters – trust framing – because isolating it is harder than swapping a headline
Most creative testing in this category still swaps headlines, images, and CTAs the same way any consumer brand would, without isolating the variable that actually drives digital health conversion: how much perceived risk and trust-building the creative does before asking for anything. That variable is harder to test cleanly, so most teams avoid it and keep optimizing surface-level elements instead.
How We Can Help
We begin by mapping your review throughput – the number of variants your legal and medical reviewers can realistically approve each week – then shape the testing cadence around that actual figure, rather than an industry-standard target that assumes there is no review gate. This establishes how many concurrent tests we can truly run.
For small, high-value audience segments, we apply sequential and Bayesian testing methods built for lower-volume data rather than imposing a standard significance threshold those segments cannot reach quickly enough to be useful. This means you can still learn from a rare-condition or narrow employer cohort instead of dismissing it as untestable.
Before launch, every test variant receives the same claim-substantiation check, whether it is likely to be a serious contender or merely a throwaway control, because the danger of an unsubstantiated claim does not decrease simply because a variant is called a test. We integrate this check into the workflow so testing is not slowed more than necessary.
We specifically prioritize the trust-framing variable – how much credibility is established before the ask, the order of risk and reassurance language, and how clinical evidence appears – because it is the lever most likely to affect digital health conversion and the one testing programs most often overlook in favor of simpler surface-level changes.
We report results with their true confidence level, including candid flags when a segment's sample size cannot support a valid conclusion, so your team does not make decisions based on noise presented as a finding. We prefer calling a test inconclusive to creating false confidence.
Unlike a standard creative testing retainer, the full cadence, sample-size methodology, and risk review are designed for the actual constraints of a regulated, small-audience, high-stakes creative environment rather than borrowed from a consumer ecommerce testing playbook.
What we deliver
- Review-throughput-calibrated testing cadence matched to your legal and medical clearance capacity
- Sequential and Bayesian testing methodology for small, high-value audience segments
- Claim-substantiation review built into every test variant before launch, not just winning creative
- Structured trust-framing tests isolating credibility sequencing as its own testable variable
- Honest confidence-level reporting that flags underpowered results instead of overstating significance
Most digital health creative testing breaks down for a structural reason rather than a creative one – it adopts a testing cadence made for unlimited variant volume and unlimited audience size, while this category offers neither.
Our Methodology
We conduct digital health creative testing as a 90-day sprint. During the first 30 days, we map your review throughput and audience segment sizes to establish a practical testing cadence and identify which segments require sequential or Bayesian methods rather than standard significance testing. Days 30 through 60 introduce the first structured testing wave, prioritizing trust framing across your largest segments while running lower-volume sequential tests for smaller, high-value cohorts. From days 60 through 90, we broaden testing coverage and deliver a framework calibrated to your real constraints.
Rather than using a standard multivariate testing playbook, we shape the cadence and statistical approach around your actual review throughput and audience sizes from day one, because applying consumer-scale testing assumptions to a regulated, segment-driven business creates false confidence more often than genuine answers. Success is measured by whether findings hold up and lead to action, not by the number of variants technically launched.
Our Working Process
The initial 30 days evaluate your review throughput and audience segment data, allowing us to create a testing cadence and methodology suited to your actual constraints instead of applying a generic multivariate testing template.
Days 30 through 60 deliver the first testing wave, focused on trust-framing variables across your largest segments and sequential testing within smaller, high-value cohorts. We need your legal and medical stakeholders to commit to review turnaround, along with access to your analytics platform so results can be monitored by segment rather than only in aggregate.
During days 60 through 90, we expand testing across more segments and creative variables, then hand over a documented framework – including cadence, sample-size thresholds, and a claim-review checklist – that your team can operate independently moving forward. Most engagements last three to six months because some segment-level tests need that long to generate reliable data.
Our cadence includes a weekly test-review call and continued async support for claim-substantiation questions while new variants are developed, as rapid claim review is essential to keeping testing from stalling.
- A testing cadence your review process can actually sustain
- Reliable read on small, high-value audience segments instead of "untestable"
- Identified trust-framing patterns that move conversion across segments
- A documented testing framework your team owns after the engagement
If your digital health company needs creative testing & iteration leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
What does creative testing cost for a digital health company?
Pricing depends on the number of audience segments and creative variables being tested at the same time, as well as how much sequential-testing methodology is required for smaller cohorts. It costs less to run testing for companies with one broad consumer audience than for those working across several narrow, condition-specific segments.
How soon can we expect results from creative testing in this category?
High-traffic segment tests may achieve confidence within a few weeks. Sequential tests for small, high-value cohorts intentionally take longer – we provide a realistic timeline upfront based on segment size instead of promising a standard testing sprint that available data volume cannot sustain.
How will your testing process integrate with our legal and medical review team?
Every variant, even those intended as throwaway controls, receives the same claim-substantiation check before going live. We incorporate this review step directly into the testing cadence, ensuring it is included in timelines rather than handled as an additional delay.
How is Winston Francois different from a typical creative testing agency?
Most testing agencies use a consumer-scale multivariate playbook regardless of the industry. We tailor the cadence and statistical methodology to your true review throughput and audience segment sizes, applying sequential and Bayesian methods when standard significance testing could not provide a useful answer in time.
How is ROI measured for a creative testing engagement?
We report lift alongside the actual confidence level for every result and monitor how many winning patterns identified through testing are incorporated into ongoing production. An honestly inconclusive result has more value than a false positive, so we assess whether testing-driven decisions remain valid over time rather than measuring raw test volume alone.
What kind of digital health company is best suited to this service?
This service suits companies already producing paid or lifecycle creative with an established legal or medical review gate, particularly those with at least one narrow, high-value audience segment previously dismissed as too small for testing. If you do not yet produce enough creative volume to test, begin there. Start with a strategy call and a review of your existing segment and review data.
